The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
Open accessAbstract
BACKGROUND: Neoadjuvant chemotherapy followed by radical cystectomy is the standard treatment for cisplatin-eligible patients with muscle-invasive bladder cancer. Adding perioperative immunotherapy may improve outcomes. METHODS: In this phase 3, open-label, randomized trial, we assigned, in a 1:1 ratio, cisplatin-eligible patients with muscle-invasive bladder cancer to receive neoadjuvant durvalumab plus gemcitabine-cisplatin every 3 weeks for four cycles, followed by radical cystectomy and adjuvant durvalumab every 4 weeks for eight cycles (durvalumab group), or to receive neoadjuvant gemcitabine-cisplatin followed by radical cystectomy alone (comparison group). Event-free survival was one of two primary end points. Overall survival was the key secondary end point. RESULTS: In total, 533 patients were assigned to the durvalumab group and 530 to the comparison group. The estimated event-free survival at 24 months was 67.8% (95% confidence interval [CI], 63.6 to 71.7) in the durvalumab group and 59.8% (95% CI, 55.4 to 64.0) in the comparison group (hazard ratio for progression, recurrence, not undergoing radical cystectomy, or death from any cause, 0.68; 95% CI, 0.56 to 0.82; P<0.001 by stratified log-rank test). The estimated overall survival at 24 months was 82.2% (95% CI, 78.7 to 85.2) in the durvalumab group and 75.2% (95% CI, 71.3 to 78.8) in the comparison group (hazard ratio for death, 0.75; 95% CI, 0.59 to 0.93; P = 0.01 by stratified log-rank test). Treatment-related adverse events of grade 3 or 4 in severity occurred in 40.6% of the patients in the durvalumab group and in 40.9% of those in the comparison group; treatment-related adverse events leading to death occurred in 0.6% in each group. Radical cystectomy was performed in 88.0% of the patients in the durvalumab group and in 83.2% of those in the comparison group. CONCLUSIONS: Perioperative durvalumab plus neoadjuvant chemotherapy led to significant improvements in event-free survival and overall survival as compared with neoadjuvant chemotherapy alone. (Funded by AstraZeneca; NIAGARA ClinicalTrials.gov number, NCT03732677; EudraCT number, 2018-001811-59.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AJCC Cancer Staging Manual. 6th ed
Greene, F., Page, D., Id, F., Fritz, J., Balch, C., & Haller, D. (2002) · Cited by 2,324
Amin, M. B., Edge, S. B., Greene, F. L., & American Joint Committee on Cancer (n.d.) · Cited by 1,365
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
Powles, T., Valderrama, B. P., Gupta, S., Bedke, J., Kikuchi, E., Hoffman-Censits, J., Iyer, G., Vulsteke, C., Park, S. H., Shin, S. J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2312117 · Cited by 1,103
Self-citationAdjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma
Bajorin, D. F., Witjes, J. A., Gschwend, J. E., Schenker, M., Valderrama, B. P., Tomita, Y., Bamias, A., Lebret, T., Shariat, S. F., Park, S. H., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034442 · Cited by 1,065
Self-citationctDNA guiding adjuvant immunotherapy in urothelial carcinoma
Powles, T., Assaf, Z. J., Davarpanah, N., Banchereau, R., Szabados, B. E., Yuen, K. C., Grivas, P., Hussain, M., Oudard, S., Gschwend, J. E., et al. (2021) · Nature · doi:10.1038/s41586-021-03642-9 · Cited by 646
Self-citationBladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Powles, T., Bellmunt, J., Comperat, E., De Santis, M., Huddart, R., Loriot, Y., Necchi, A., Valderrama, B. P., Ravaud, A., Shariat, S. F., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2021.11.012 · Cited by 555
Self-citationNivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma
van der Heijden, M. S., Sonpavde, G., Powles, T., Necchi, A., Burotto, M., Schenker, M., Sade, J. P., Bamias, A., Beuzeboc, P., Bedke, J., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2309863 · Cited by 511
Self-citationPfister, C., Gravis, G., Fléchon, A., Chevreau, C., Mahammedi, H., Laguerre, B., Guillot, A., Joly, F., Soulié, M., Allory, Y., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02051 · Cited by 215
Holzbeierlein, J., Bixler, B. R., Buckley, D. I., Chang, S. S., Holmes, R. S., James, A. C., Kirkby, E., McKiernan, J. M., & Schuckman, A. (2024) · Journal of Urology · doi:10.1097/ju.0000000000003981 · Cited by 211
Szabados, B., Kockx, M., Assaf, Z. J., van Dam, P.-J., Rodriguez-Vida, A., Duran, I., Crabb, S. J., Van Der Heijden, M. S., Pous, A. F., Gravis, G., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.04.013 · Cited by 209
Self-citationRose, T. L., Harrison, M. R., Deal, A. M., Ramalingam, S., Whang, Y. E., Brower, B., Dunn, M. W., Osterman, C. K., Heiling, H., Bjurlin, M. A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01003 · Cited by 151
Hu, J., Chen, J., Ou, Z., Chen, H., Liu, Z., Chen, M., Zhang, R., Yu, A., Cao, R., Zhang, E., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100785 · Cited by 148
A recycling framework for the construction of Bonferroni‐based multiple tests
Burman, C., Sonesson, C., & Guilbaud, O. J. M. (2009) · Statistics in Medicine · doi:10.1002/sim.3513 · Cited by 140
Sonpavde, G., Necchi, A., Gupta, S., Steinberg, G. D., Gschwend, J. E., Heijden, M. S. V. D., Garzon, N., Ibrahim, M. F. K., Raybold, B., Liaw, D., et al. (2019) · Future Oncology · doi:10.2217/fon-2019-0611 · Cited by 101
Self-citationGalsky, M. D., Guan, X., Rishipathak, D., Rapaport, A. S., Shehata, H. M., Banchereau, R., Yuen, K. C. Y., Varfolomeev, E. E., Hu, R., Han, C.-J., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101393 · Cited by 75
Self-citationKamat, A. M., Apolo, A. B., Babjuk, M., Bivalacqua, T. J., Black, P. C., Buckley, R., Campbell, M. T., Compérat, É., Efstathiou, J. A., Grivas, P. D., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00307 · Cited by 66
Self-citationCathomas, R. L., Rothschild, S. I., Hayoz, S., Bubendorf, L., Özdemir, B. C., Kiss, B. M., Erdmann, A. A., Aeppli, S., Mach, N., Strebel, R. T., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00363 · Cited by 56
Kim, H.-S., Jeong, B. C., Hong, J., Kwon, G. Y., Kim, C. K., Park, W., Pyo, H., Song, W., Sung, H. H., Hong, J. Y., et al. (2022) · Cancer Research and Treatment · doi:10.4143/crt.2022.343 · Cited by 33
Chanzá, N. M., Soukane, L., Barthélémy, P., Carnot, A., Gil, T., Casert, V., Vanhaudenarde, V., Sautois, B. R., Staudacher, L., den Brande, J. V., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08990-3 · Cited by 22
Chang, E., Apolo, A. B., Bangs, R., Chisolm, S., Duddalwar, V. A., Efstathiou, J. A., Goldberg, K. B., Hansel, D. E., Kamat, A. M., Kluetz, P. G., et al. (2021) · Nature Reviews Urology · doi:10.1038/s41585-021-00505-w · Cited by 18
Self-citationThibault, C., Elaidi, R., Vano, Y. A., Rouabah, M., Braychenko, E., Helali, I., Audenet, F., & Oudard, S. M. (2020) · Bulletin du Cancer · doi:10.1016/s0007-4551(20)30281-2 · Cited by 17
Sarkis, J., Vannier, E., Mjaess, G., Pochet, C., Albisinni, S., Quackels, T., & Roumeguère, T. (2022) · Immunotherapy · doi:10.2217/imt-2022-0039 · Cited by 7
Cited by
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
Janjigian, Y. Y., Al-Batran, S.-E., Wainberg, Z. A., Muro, K., Molena, D., Van Cutsem, E., Hyung, W. J., Wyrwicz, L., Oh, D.-Y., Omori, T., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2503701 · Cited by 333
Metadata
- Authors
- Powles, T., Catto, J. W. F., Galsky, M. D., Al-Ahmadie, H., Meeks, J. J., Nishiyama, H., Vu, T. Q., Antonuzzo, L., Wiechno, P., Atduev, V., Kann, A. G., Kim, T.-H., Suárez, C., Chang, C.-H., Roghmann, F., Özgüroğlu, M., Eigl, B. J., Oliveira, N., Buchler, T., Gadot, M., Zakharia, Y., Armstrong, J., Gupta, A., Hois, S., & van der Heijden, M. S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-11-14
- Volume
- 391
- Issue
- 19
- Pages
- 1773-1786
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4402552345
- Cited by
- 415
- References
- 22
- FWCI
- 158.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.